Drugs / RG-7602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01359696 | Jul 2011 → May 2014 | cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314388 ↗ |
| Known as | GDC-0425 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01359696 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL5314388 ↗ |
| Modality | Small molecule | — CHEMBL5314388 ↗ |
| Route | Oral | “Oral escalating dose” NCT01359696 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL5314388 ↗ |